Novartis (NVS) said Friday the US Food and Drug Administration has approved its radioligand therapy Pluvicto for earlier use before chemotherapy in prostate cancer patients.

The new indication allows the use in patients with metastatic castration-resistant prostate cancer who have been treated with an androgen receptor pathway inhibitor therapy and are considered appropriate to delay chemotherapy, Novartis said.

The approval triples the number of patient population eligible to receive Pluvicto, the company said.

Price: 112.29, Change: +0.89, Percent Change: +0.80